Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Qatar LNG Tanker Crosses Strait of Hormuz Amid Iran War Tensions 
Russia Accuses Ukraine of Ceasefire Violations Amid Drone and Artillery Attacks 
China-Made Fireworks Power U.S. Independence Day Celebrations Amid Trade Truce 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Pope Leo Calls for Peace as Vatican Seeks Better Ties With U.S. 
Malaysia Unveils Energy Security Plan Amid Iran Conflict and Rising Oil Costs 
Ukraine-Russia Ceasefire Confirmed as Prisoner Swap Deal Advances 
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions 
Japan’s Yen Intervention and BOJ Rate Hike Bets Support Currency Recovery 
Senate Stablecoin Bill Sparks Clash Between Banks and Crypto Industry 
Google Secures Pentagon AI Deal for Classified Projects 
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers 
U.S. Flags Vietnam as “Priority Foreign Country” Over Intellectual Property Concerns 
Federal and State Authorities Conduct Widespread Fraud Raids Across Minnesota 
Trump-Xi Meeting 2026: U.S.-China Trade Tensions Escalate Ahead of Beijing Summit 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
